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Abstract
Background: Granulocyte-colony stimulating factor (G-CSF) is known as a powerful regulator of
white blood cell proliferation and differentiation in mammals. We, and others, have shown that G-
CSF is effective in treating cerebral ischemia in rodents, both relating to infarct size as well as
functional recovery. G-CSF and its receptor are expressed by neurons, and G-CSF regulates
apoptosis and neurogenesis, providing a rational basis for its beneficial short- and long-term actions
in ischemia. In addition, G-CSF may contribute to re-endothelialisation and arteriogenesis in the
vasculature of the ischemic penumbra. In addition to these trophic effects, G-CSF is a potent
neuroprotective factor reliably reducing infarct size in different stroke models.
Results: Here, we have further delayed treatment and studied effects of G-CSF on infarct volume
in the middle cerebral artery occlusion (MCAO) model and functional outcome in the cortical
photothrombotic model. In the MCAO model, we applied a single dose of 60 μg/kg bodyweight G-
CSF in rats 4 h after onset of ischemia. Infarct volume was determined 24 h after onset of ischemia.
In the rat photothrombotic model, we applied 10 μg/kg bodyweight G-CSF daily for a period of 10
days starting either 24 or 72 h after induction of ischemia. G-CSF both decreased acute infarct
volume in the MCAO model, and improved recovery in the photothrombotic model at delayed
timepoints.
Conclusion: These data further strengthen G-CSF's profile as a unique candidate stroke drug, and
provide an experimental basis for application of G-CSF in the post-stroke recovery phase.
Background
Granulocyte-colony stimulating factor (G-CSF) is a
cytokine that stimulates generation of neutrophilic granu-
locytes, and has been in clinical use for more than 10 years
in indications related to counteracting neutropenia, or for
bone-marrow transplantations [1-3]. Recently, a surpris-
ing activity of G-CSF in protecting against experimental
cerebral ischemia has been shown by a large number of
laboratories [4-12]. The explanations for the effects of G-
CSF on the CNS appear as a combination of direct anti-
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apoptotic activity on neurons [5,6,13] mediated by the
presence of the cognate G-CSF receptor in a broad array of
brain regions [14], stimulation of endogenous neurogen-
esis [14], regeneration of vascularisation [8], potential
mobilisation of bone-marrow derived cells that migrate to
the brain [11,12], and possible systemic anti-inflamma-
tory effects ([15], discussed in [14]).
Characterised by this multimodal array, G-CSF appears
beneficial for short-term damage parameters such as inf-
arct size, and long-term effects on functional outcome (for
example, see [6]). Based on this broad pre-clinical basis
for efficacy, G-CSF is now undergoing testing in clinical
trials by three different groups, primarily aimed at demon-
strating safety in human stroke patients (reviewed in
[16]).
Here we further explore the window of opportunity for G-
CSF treatment in firstly, the most accepted model for eval-
uating neuroprotective effects, rat middle cerebral artery
occlusion (MCAO), and secondly, the cortical photo-
thrombotic stroke model for detecting effects on long-
term functional outcome.
Results
Neuroprotective activity of G-CSF after delayed treatment
We recently reported an infarct-reducing capacity of G-
CSF after middle cerebral artery occlusion (MCAO) when
treatment was initiated at 30 min and 2 h after onset of
ischemia [5,6]. Here we delayed treatment with G-CSF (60
μg/kg body weight i.v.) to 4 h after vessel occlusion. In
addition, we analysed cortical and subcortical infarct vol-
umes separately to determine relative protection levels in
these areas. Infarct size was measured 24 h after induction
of ischemia by TTC-staining. We obtained both direct inf-
arct volumes (including edema volume) as well as indirect
infarct volumes (contralateral minus ipsilateral non-inf-
arcted volume) that do not contain edema under the
assumption that edema formation is confined to infarcted
areas. This also allowed us to deduct the edema volume
for each animal.
We observed a robust infarct volume reduction by 33 % in
the total infarct volume as compared to vehicle-treated
rats (334.0 ± 31.5 mm3 (n = 24) vs. 223.3 ± 27.3 mm3 (n
= 18), p < 0.05; Figure 1A). This effect was significant in
both the cortical (35% reduction; 223.6 ± 25.5 mm3 vs.
144.3 ± 22.7 mm3; p < 0.05) as well as the subcortical
(28% reduction; 110.3 ± 9.7 vs. 78.9 ± 6.3 mm3; p < 0.01)
part of the infarction.
Relative infarct size reduction was equal after edema cor-
rection (34% reduction in total infarct size; 261.5 ± 24.9
mm3 vs. 171.4 ± 19.4 mm3; p < 0.01, Fig. 1B), with 38%
reduction in cortical volume (p < 0.05) and 27% in sub-
cortical volume, which missed statistical significance (p =
0.076). There was no difference in mortality nor in several
operational parameters obtained, such as oxygen satura-
tion after the operation, the drop of cortical perfusion as
monitored by Laser-Doppler flowmetry, or duration of
the operation (data not shown).
G-CSF improves functional outcome after cerebral 
ischemia
For measuring long-term effects of G-CSF treatment we
applied photothrombotic induction of ischemia in the
sensorimotor cortex, as this model produces defined neu-
rological deficits without affecting survival. Previously we
have shown a strong influence of G-CSF on functional
outcome in the cortical photothrombotic model [6].
There, the first treatment was given 1 h after ischemia. To
determine whether a more delayed initiation of treatment
with G-CSF also induces a long-term sensorimotor func-
tional improvement, we designed an experiment where G-
CSF was given at 24 and 72 h after ischemia for
10consecutive days at a dose of 10 μg/kgbodyweight.
Sensorimotor deficits in the rotarod test were obvious in
vehicle-treated ischemic animals compared to sham-oper-
ated rats in the rotarod for up to 6 weeks after the insult
(Figure 2A). G-CSF treated ischemic rats in both the 24 h
and 72 h time-window performed significantly better in
the rotarod test than vehicle-treated animals when com-
paring group means per timepoint (Figure 2A). We also
used another more appropriate test for time-series meas-
urements in subjects, and compared areas under the indi-
vidual curves over time (AUC) (Figure 1A, bar graphs).
This data representation also demonstrated a robust
improvement in sensorimotor function of G-CSF treat-
ment over vehicle (ANOVA followed by SNK post hoc test;
compare bars). There was no significant difference
between the 24 and 72 h time window. Finally, we com-
pared linear regressions of the vehicle-treated ischemia
group, and the 72 h G-CSF treatment group (Figure 2B).
This analysis demonstrated a significant difference in the
slopes of both regression lines (p < 0.01), indicating a
truly enhanced slope of recovery for the delayed G-CSF
treatment. Physiological parameters (rectal temperature,
pH, pCO2, pO2, and mean arterial pressure during sur-
gery) did not differ between the groups. In addition, there
were no differences in mortality or body weight between
all groups (not shown).
Discussion
Infarct size reduction
Here we demonstrate a robust infarct-reducing effect of a
4 h treatment delay with G-CSF in a severe hemispheric
stroke model (MCAO), viewed as the gold standard for
testing neuroprotective effects. The end point for deter-
mining infarct volume was 24 h following onset ofBMC Biology 2006, 4:36 http://www.biomedcentral.com/1741-7007/4/36
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G-CSF reduces cortical and subcortical infarct volume in the rat MCAO model when applied 4 h after onset of ischemia Figure 1
G-CSF reduces cortical and subcortical infarct volume in the rat MCAO model when applied 4 h after onset of ischemia. A. 
Shown are infarct volumes for the total infarct, cortical and subcortical areas. Infarct volumes were determined 24 h after 
onset of ischemia by TTC-staining and planimetry. B. Infarct volumes after edema correction. Edema-corrected infarct volumes 
were obtained by deducting the non-infarcted ipsilateral hemisphere volume from the contralateral hemisphere volume. Vol-
umes are given in mm3 as means ± SEM.
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G-CSF improves functional outcome when given as late as 72 h after photothrombotic ischemia Figure 2
G-CSF improves functional outcome when given as late as 72 h after photothrombotic ischemia. A. Design of the cortical pho-
tothrombotic experiment. B. Rotarod performance over the course of 6 weeks after ischemia. Rats received 10 μg/kg body-
weight/day G-CSF for 10 days starting either at 24 or 72 h after ischemia. The effect is also detectable by an analysis of 
individual areas-under-the-curve (AUC). (*,#: p < 0.05 by ANOVA and Student-Newman-Keuls post-hoc test for 24 h (#) and 
72 h (*) treatment). C. Linear regression analysis of vehicle treatment and G-CSF treatment initiated at 72 h demonstrates that 
slopes are significantly different by a factor of 2 (p = 0.004)
*
100
200
300
400
500
123456
weeks post ischemia
s
e
c
o
n
d
s
ischemia ischemia + G-CSF 72h sham ischemia + G-CSF 24h
*
* *
*
#
#
500
1000
1500
2000
2500
A
U
C
#
y = 16.783x + 162.86
y = 32.786x + 168.4
0
100
200
300
400
500
01234567
weeks
s
e
c
o
n
d
s
*
Photothrombotic ischemia
week 0 123456
24 h group treatment
72 h group treatment
A
B
C
Training
TestingBMC Biology 2006, 4:36 http://www.biomedcentral.com/1741-7007/4/36
Page 5 of 8
(page number not for citation purposes)
ischemia, a standard timepoint for neuroprotective stud-
ies. We know, however, that the effect of G-CSF is not
transient as has been discussed with some experimental
drugs, but is also detectable when examining the brain at
72 h post ischemia after a combined CCA/distal MCA
occlusion [6]. The achieved total reduction in infarct vol-
ume of 34.5% is an extension of previous studies in the
same model where treatment was initiated 30 min [5] and
2 h [6] after onset of ischemia. We also demonstrate for
the first time a clear treatment effect both on cortical as
well as subcortical areas with a meaningful sample size
per group. This is important, as the effect of a number of
neuroprotective drugs has been shown to be limited to the
cortex, e.g. [17]. The neuroprotective acitivity of G-CSF in
a broader range of brain regions can be explained by the
broad distribution of the G-CSF receptor in the brain [6].
However, the effect on lesion volume in the cortex is more
pronounced than in the subcortex, which is either
explained by the relative distribution of infarct core and
presumptive penumbra to striatum and cortex in the
MCAO filament model, or indeed demonstrates a
stronger protective effect in the cortex.
Support for a delayed window of opportunity for G-CSF
in acute stroke models comes from three other independ-
ent studies. Treatment effects were investigated in compar-
atively mild ischemia models producing small
hemispheric or cortical infarctions appropriate to assess
recovery effects rather than to test the neuroprotective
potential of a drug in the acute phase. Six et al. have
shown a stunning 55% infarct reducing effect when treat-
ment was delayed for 24 h after transient MCAO in the
mouse with a relatively small sample size of n = 6 per
group [4]. Komine-Kobayashi et al. demonstrated a
decreased infarct size in the same model after initiation of
G-CSF treatment 24 h and 72 h after the infarct [7]. Shyu
et al. reported effects on infarct size when treatment was
initiated as late as 24 h after the insult in a rat combined
CCA/distal MCA model with 90 min occlusion of the dis-
tal MCA, which produces purely cortical infarcts [12].
Although these studies have used milder models, it
appears probable from the cumulated evidence that the
window of opportunity in a severe hemispheric stroke
model could be also considerably longer than 4 h, espe-
cially in view of the still sizable treatment effect observed
at this point. It is therefore desirable to further explore this
acute time window and define the timepoint where effi-
cacy is lost.
By comparing the differences of total infarct volumes
without and with edema correction, our data indicate an
absolute reduction in edema volume in favor for G-CSF
(compare 51.9 mm3 to 72.5 mm3 in the vehicle treated
group, Figure 1). This seems to be in agreement to the data
generated by Gibson et al [10] who have seen edema
reduction in both transient and permanent MCAO after
G-CSF treatment. There, the authors have used a direct
method to determine edema by measuring brain total
water content by the dry weight method. However, as it is
well known that larger infarcts produce more vasogenic
edema, it is important to relate the edema volume to the
infarct volumes in the respective groups to exclude edema
reduction simply as a consequence of reduced infarct vol-
ume. Here, the edema volume is in similar proportion to
the total infarct size in both the vehicle (21.7%) and the
G-CSF group (23.2%). Thus, there is no evidence for a sep-
arate effect on edema extent by G-CSF treatment. As there
are no data in the work mentioned above to estimate the
relative edema extent to infarct sizes, which are decreased
by G-CSF treatment, it is difficult at the moment to judge
whether the data can be truly interpreted as an independ-
ent edema-reducing effect of G-CSF.
Long-term effects
We have previously already demonstrated significant
activity of G-CSF towards enhancing post-stroke recovery
in the photothrombotic model in conjunction with stim-
ulation of neurogenesis by using a diligent assessment of
sensorimotor function [6]. In this previous experiment we
have applied a five-day treatment of G-CSF at 15 μg/kg
bodyweight/day starting with the first dose 1 h after
induction of ischemia. Therefore it is possible that part of
the recovery effect seen is due to the acute antiapoptotic
property of G-CSF. To minimise any acute effects on inf-
arct size, and define time windows for G-CSF's pro-regen-
erative functions after stroke, we delayed the initial
treatment to 24 and 72 h post ischemia. In addition, we
chose a dosage scheme that appears clinically safe and fea-
sible for a treatment period of weeks, 10 days of 10 μg/kg
bodyweight daily. This application scheme is similar to
the one used in the previous recovery experiment, but has
a longer duration and lower single doses of G-CSF. This
scheme is also readily translatable to an explorative study
in stroke patients for testing the pro-regenerative potential
in man. For exploring the therapeutic time window for
initiation of a recovery-enhancing effect post-stroke we
have here concentrated on a robust parameter, time to fall
off the rotarod device. The course of the curves for all
ischemic groups neatly demonstrates that the groups only
start to separate in the second week of the experiment, and
highlight that the initial value post-stroke is absolutely
identical, indicating that there was no difference in the
extent of the initial damage in this model relevant to sen-
sorimotor performance. Thus, we have reached our goal
to uncouple acute neuroprotective effects of G-CSF from
effects on long-term recovery.
Surprisingly, a recovery-enhancing effect at the 72 h
delayed treatment initiation was still clearly detectable,
and not significantly different from the initiation at 24 h.BMC Biology 2006, 4:36 http://www.biomedcentral.com/1741-7007/4/36
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This indicates that the window of opportunity for pure
recovery enhancement with G-CSF may not be time-
dependent in the same way as therapeutic effects in the
acute phase after stroke. Indeed, there is no statistical dif-
ference between the 24- and 72-h initiation of treatment.
A substantial window of opportunity for improvements in
functional outcome by G-CSF treatment is also suggested
by Lees et al. [8], who report effects in rotarod measure-
ments particularly when treatment was delayed to 1 day
and longer after MCAO.
It will now be very interesting to further delay treatment
and to define the limits of G-CSF efficacy in such models.
There is a surprising scarcity of data relating to the charac-
terisation of susceptible post-stroke time periods for
recovery processes in the rodent. In light of the neurogen-
esis-enhancing effects of G-CSF it is highly interesting
that, at least for ischemia-induced neurogenesis, there is
no clear time dependence from the insult, and increased
neurogenesis may keep up for months after stroke [18],
thereby likely providing a long period of susceptibility to
therapeutic interference by neurogenesis-enhancing sub-
stances such as G-CSF.
Implications for the clinic
Here, we have further delineated a truly bimodal efficacy
of G-CSF both for acute effects on infarct size, as well as
on chronic enhancement of post-stroke recovery.
Together with a substantial body of evidence for efficacy
of G-CSF in varied stroke models (reviewed in [14]) our
data further strengthen confidence in the potential of G-
CSF for the treatment of human stroke.
In addition to a rational mode-of-action within stroke
pathophysiology, any candidate for further stroke drug
development should be explored according to the STAIR
criteria [19]. G-CSF fulfills these criteria well: blood-brain-
barrier penetration, neuroprotective activity in different
stroke models including permanent ischemia demon-
strated by independent groups, activity shown in different
species, well-known pharmakocinetics, as well as func-
tional outcome data. Likewise, data on the potential ther-
apeutic time window are important. We have recently
shown that G-CSF is neuroprotective until at least 2 h
post-stroke in a severe focal cerebral ischemia model [6].
As indicated by the present results, G-CSF is effective
when treatment is delayed as late as 4 h post-stroke.
Although conversions to the human situation are delicate,
a 4-h time window in this stroke model may relate to a
therapeutic time window in humans of several hours.
The effect on functional outcome appears as a separable
activity of G-CSF, independent of its neuroprotective
potential. This makes G-CSF a highly attractive candidate
for recovery enhancement in the subacute or chronic
phase of a stroke and increases the likelihood for detecting
clinical outcome improvement in acute stroke trials.
Conclusion
Aiming at the two principal modes-of-action of G-CSF in
the brain, antiapoptosis and regeneration enhancement,
we have both studied effects on infarct size with delayed
treatment in a severe MCAO model, as well as functional
sensorimotor outcome in the cortical photothrombotic
model. We find that G-CSF has an acute time window of
at least 4 h post-stroke, and an astonishing time window
for effects on functional outcome of three days after
stroke. The strong effects on functional outcome distuin-
guish G-CSF from most other candidate stroke drugs in
development.
Our findings further strengthen confidence in the efficacy
of G-CSF both for infarct size reduction, and improve-
ment of functional parameters, and are important guiding
lines for future clinical development.
Methods
Suture occlusion model
Male Wistar rats weighing 280 to 320 g received inhala-
tion anesthesia with 70%N2O, 30% O2, and 1% haloth-
ane. The right femoral vein was cannulated and used for
drug delivery. During the experiment, core body tempera-
ture was monitored and maintained at 37°C by a thermo-
statically controlled heating pad (Föhr Medical
Intruments). Middle cerebral artery occlusion (MCAO)
was induced with a silicon-coated (Provil Novo, Heraus
Kulzer) 4-0 nylon filament (Ethicon) that was introduced
into the common carotid artery and advanced into the
internal carotid artery as described previously [5]. Success-
ful MCA occlusion was verified by Laser-Doppler flowme-
try (Perimed 4000) with a probe positioned over the
cortical MCA territory. After 90 min MCAO, the filament
was withdrawn to allow for reperfusion. Four hours after
onset of occlusion animals received 60 μg/kg G-CSF
(Neupogen, AMGEN) i.v. over 20 min or vehicle.
Infarct and edema volume
Infarct volumes were determined 24 h after induction of
ischemia by TTC staining as described previously [5]. 2
mm sections were cut using a brain matrix (Harvard Appa-
ratus, Inc.), and stained with 2,3,5-Triphenyl tetrazolium
chloride (TTC, Sigma-Aldrich) for 10 min at 37°C.
Stained sections were scanned on both sides using a color
scanner, and infarct areas determined using ImageJ v 1.33
[20]. "Direct" infarct volume was obtained by integrating
measured infarcted areas, "indirect" infarct volume was
obtained by deducting the non-infarcted volume of the
infarcted hemisphere from the contralateral hemisphere.
As edema mostly develops in the infarcted areas, the
"direct" volume contains edema, and "direct" minusBMC Biology 2006, 4:36 http://www.biomedcentral.com/1741-7007/4/36
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"indirect" volume gives the edema volume (see also [5]).
Animals with any signs of subarachnoid hemorrhage (bar-
rel-rolling, or blood in the ventricles or subarachnoid
space), any cortical damage from drill holes, and no or
minimal infarcts on TTC-staining were excluded from the
analysis before unblinding.
Photothrombotic ischemia model
Male Wistar rats were anesthetised with an intramuscular
injection of 100 mg/kg bodyweight ketaminehydrochlo-
ride (Ketanest) and 8 mg/kg bodyweight xylazine hydro-
chloride (Rompun). Anesthesia was maintained with 50
mg/kg bodyweight ketaminehydrochloride and 4 mg/kg
bodyweight xylazine hydrochlorideif necessary. A PE-50
polyethylene tube was inserted into the right femoral
artery for continuous monitoring of mean arterial blood
pressure, and blood gases. The right femoral vein was can-
nulated by a PE-50 tube for treatment infusion. During
the experiment rectal temperature was monitored and
maintained at 37°C by a thermostatically controlled heat-
ing pad (Föhr Medical Intruments). Photothrombotic
ischemia was induced in the rat parietal cortex according
to the method of Watson et al. [21]. Animals were placed
in a stereotaxic frame, and the scalp was incised for expo-
sure of the skull surface. For illumination, a fiber-optic
bundle with a 1.5-mm aperture was placed stereotaxically
onto the skull 4 mm posterior to the bregma and 4 mm
lateral from the midline. The skull was illuminated with a
cold, white light beam (150 W) for 20 minutes. During
the first 2 min of illumination, the dye rose bengal (0.133
mL/kg body weight, 10 mg/mL saline) was injected intra-
venously. Sham-operated animals underwent the same
experimental procedures as described above without infu-
sion of rose bengal and illumination. After surgery, the
catheters were removed, and the animals were allowed to
recover from the anesthesia and given food and water ad
libitum. For treatment, ischemic or sham-operated ani-
mals were given vehicle (n = 10) or 10 μg G-CSF/kg bod-
yweight i.v. starting 24 (n = 10) or 72 hours (n = 10) after
induction of ischemia. Daily repeated i.v. bolus infusions
via the tail vein (G-CSF or vehicle) followed on the fol-
lowing 10 days.
Behavioral measurements
In all animals Rotarod testing was performed during the
light cycle before ischemia after a training period of 3
days, and at 1,2,3,4,5 and 6 weeks after ischemia by an
investigator blinded to the experimental groups. Rats were
placed on an accelerating Rotarod cylinder (increased
speed from 4 to 40 rpm within 5 min). The time the ani-
mals remained on the Rotarod was measured, and the trial
ended if the animal fell off the rungs or gripped the device
and spun around for two consecutive revolutions without
attempting to walk on the rungs. An arbitrary time limit of
500 sec was set for the rats on the Rotarod cylinder in
training and in the testing procedures. The animals were
trained 3 days before ischemia, and the mean duration
(sec) on the device was recorded with three measure-
ments.
All animal experiments were performed in accordance
with national and international regulations, and were
approved by the appropriate government authorities. All
experiments were performed in a fully randomised and
blinded fashion.
Data and Statistical analysis
The values presented in this study are means ± SEM. The
two-tailed t-test was used to determine significant differ-
ence of infarct volumes. Behavioural measurements were
analysed using ANOVA and the Student-Newman-Keuls
post hoc test. Area under the curve (AUC) was calculated
using the trapezoidal algorithm. Linear regressions were
compared using coincidence testing. Statistics were per-
formed with NCSS 2004 (NCSS Statistical Software) or
Primer of Biostatistics software. A p value <0.05 was con-
sidered statistically significant.
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